APG Asset Management N.V. Purchases 13,832 Shares of Edwards Lifesciences Co. (NYSE:EW)

APG Asset Management N.V. increased its position in Edwards Lifesciences Co. (NYSE:EW) by 2.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 492,537 shares of the medical research company’s stock after buying an additional 13,832 shares during the period. APG Asset Management N.V. owned about 0.08% of Edwards Lifesciences worth $42,450,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences in the 2nd quarter worth $29,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $34,000. Webster Bank N. A. purchased a new position in shares of Edwards Lifesciences during the second quarter valued at about $39,000. Finally, Versant Capital Management Inc increased its holdings in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price target for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Barclays decreased their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $102.00 to $70.00 in a research report on Thursday, July 25th. Finally, Evercore ISI dropped their price target on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a research report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $79.82.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,250 shares of company stock valued at $1,218,138. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.2 %

Shares of NYSE:EW opened at $66.58 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average is $68.18 and its 200 day moving average is $82.19. The stock has a market cap of $40.12 billion, a P/E ratio of 28.70, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.